Purpose: To evaluate the feasibility and safety of thulium:yttrium-aluminium-garnet laser vapoenucleation of the prostate (ThuVEP) in patients with chronic anticoagulation and bleeding disorders. Methods: We retrospectively analyzed the clinical data (transfusion rate, hemoglobin changes, residual urine, bleeding complications, complications and residual urine) of patients with chronic anticoagulation and bleeding disorders treated with ThuVEP. Anticoagulation was not paused for surgery. Results: We identified 39 patients who fulfilled the inclusion criteria (32 with chronic anticoagulation, 3 with bleeding disorder, and 4 with both). Mean preoperative hemoglobin was 12.9 g/l; the postoperative hemoglobin was 11.7 g/l. One patient received a blood transfusion. Mean residual urine was 166 ml preoperatively and 47 ml postoperatively, respectively; spontaneous voiding postoperatively was feasible in 36 patients. During follow-up, 5 patients suffered from gross hematuria, which was treated conservatively. Conclusions: ThuVEP is a safe procedure in patients with therapeutic anticoagulation, bleeding disorders and platelet aggregation inhibitor medication.

Keywords:
Bleeding disorder, Thulium laser, Benign prostatic hyperplasia, Anticoagulation
1.
Mamoulakis C, Ubbink DT, de la Rosette JJ: Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol 2009;56:798–809.
2.
Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, Devonec M, Fourmarier M, Saussine C, Barry-Delongchamps N, de la Taille A: Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 2011;29:211–216.
3.
Ahmed I, Gertner E, Nelson WB, House CM, Dahiya R, Anderson CP, Benditt DG, Zhu DW: Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm 2010;7:745–749.
4.
Dotan ZA, Mor Y, Leibovitch I, Varon D, Golomb J, Duvdevani M, Ramon J: The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 2002;168:610–613, discussion 614.
5.
Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR: A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 2003;170:1270–1274.
6.
Hai MA: Photoselective vaporization of prostate: five-year outcomes of entire clinic patient population. Urology 2009;73:807–810.
7.
Ruszat R, Seitz M, Wyler SF, Abe C, Rieken M, Reich O, Gasser TC, Bachmann A: GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol 2008;54:893–901.
8.
Rieken M, Ebinger Mundorff N, Bonkat G, Wyler S, Bachmann A: Complications of laser prostatectomy: a review of recent data. World J Urol 2010;28:53–62.
9.
Bach T, Netsch C, Haecker A, Michel MS, Herrmann TR, Gross AJ: Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up. World J Urol 2010;28:39–43.
10.
Szlauer R, Gotschl R, Razmaria A, Paras L, Schmeller NT: Endoscopic vaporesection of the prostate using the continuous-wave 2-microm thulium laser: outcome and demonstration of the surgical technique. Eur Urol 2009;55:368–375.
11.
Bach T, Wendt-Nordahl G, Michel MS, Herrmann TR, Gross AJ: Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol 2009;27:541–545.
12.
Bach T, Xia SJ, Yang Y, Mattioli S, Watson GM, Gross AJ, Herrmann TR: Thulium: YAG 2 mum cw laser prostatectomy: where do we stand? World J Urol 2010;28:163–168.
13.
Qualitätssicherung: Bundesgeschäftsstelle Kapitel 13: Prostataresektion. Qualitätsreport. Düsseldorf, Bundesgeschäftsstelle Qualitätssicherung GmbH, 2002, pp 138–149.
14.
Parr NJ, Loh CS, Desmond AD: Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. Br J Urol 1989;64:623–625.
15.
Chakravarti A, MacDermott S: Transurethral resection of the prostate in the anticoagulated patient. Br J Urol 1998;81:520–522.
16.
Raj MD, McDonald C, Brooks AJ, Drummond M, Lau HM, Patel MI, Bariol SV, Wang AC, Woo HH: Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications. Urology 2011;78:1380–1384.
17.
Hebert PR, Hennekens CH: An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med 2000;160:3123–3127.
18.
Chung DE, Wysock JS, Lee RK, Melamed SR, Kaplan SA, Te AE: Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol 2011;186:977–981.
19.
Vavassori I, Hurle R, Vismara A, Manzetti A, Valenti S: Holmium laser enucleation of the prostate combined with mechanical morcellation: two years of experience with 196 patients. J Endourol 2004;18:109–112.
20.
Fagerström T, Nyman CR, Hahn RG: Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique: a single-centre randomized trial of 202 patients. BJU Int 2010;105:1560–1564.
21.
Ho HS, Yip SK, Lim KB, Fook S, Foo KT, Cheng CW: A prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) system. Eur Urol 2007;52:517–522.
22.
Okamura K, Nojiri Y, Seki N, Arai Y, Matsuda T, Hattori R, Hasegawa T, Naito S: Perioperative management of transurethral surgery for benign prostatic hyperplasia: a nationwide survey in Japan. Int J Urol 2011, E-pub ahead of print.
23.
Elzayat E, Habib E, Elhilali M: Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 2006;175:1428–1432.
24.
Ruszat R, Wyler S, Forster T, Reich O, Stief CG, Gasser TC, Sulser T, Bachmann A: Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 2007;51:1031–1038, discussion 1038–1041.
25.
Bach T, Herrmann TR, Haecker A, Michel MS, Gross A: Thulium:yttrium-aluminium-garnet laser prostatectomy in men with refractory urinary retention. BJU Int 2009;104:361–364.
26.
Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ: RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol 2007;25:257–262.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.